Week 8 Assignment 2 21st Leadership Essay

| 1. Complete the Teamwork section of the course of study. 2. Schedule and conduct first team meeting (Note: Detailed instructions for scheduling the first team meeting can be found in the course of study.) 3. Complete the Team Contract and have team leader submit to

In the changing business environment, leaders of all organisations may face unprecedented uncertainty, especially the technology advancement and changes among the employees. To survive and succeed, leaders should have some necessary attributes. Meanwhile, some changes for leadership skills have to be made to confront the challenges.

In this individual discussion post, a review of the acquisition of Wellcome by Glaxo is explored with focus on the complexities of Wellcome’s business structure with Promedico. Additional focus is placed on Ofra Sherman, manager of Wellcome Israel, as to her history with the company, team interactions, reporting chain, and her reactions to the pending acquisition.

Ultimately these factors would result in my behaviour being that of an affiliative and democratic style of leadership. It is also possible that a coaching style my also become apparent, where the factor is that of a personal situation.

He had great plans for the company and wanted to turn it into a global giant. He applied his skills, and after some few years, the company had increased its capacity. Within five years in the industry, the company’s sales expanded from 3000 units to 12,000 freight cars by 1999. They also raised employees from only 600 to over 3,000 and the figure keeps on expanding. He aims at nothing else but just success. The company under his leadership have received so many performance-related awards, and its success stories have been awesome. Success has been witnessed, and they are still

The core leaders that govern Bristol-Myers Squibb have been stable for the past 4 years. The current Chairman of the Board of Directors, James Cornelius, MBA, was chosen in May 2010 after being CEO of BMS from 2006-2008. The following individuals are board members for BMS. Giovanni Caforio has been the Chief Operations Officer since May 2010, and a board member since 2009. He has a MD degree from the University of Rome. Lewis Campbell is a retired Chairman and former CEO of Textron with a BS in mechanical engineering. Laurie Glimcher is heavily involved with Cornell Medical College and University as provost since 2012; she received her MD from Harvard. Michael Grobstein is a retired vice chairman and partner of Ernst and Young with a CPA and Bachelor’s degree in accounting. Alan Lacy is Senior Advisor to Oak Hill Capital Partners and received his MBA from Emory University. Thomas Lynch Jr is highly involved at Yale Medical School and is Director of the Yale Cancer Center after having received his MD from Yale. Dinesh Paliwal is the CEO of Harman International Industries with an MBA and MS in Engineering from Miami University. Gerald Storch is Chairman and CEO of Storch Advisors with an MBA from Harvard. Vicki Sato is a Professor of Management Practice at Harvard with an AM and PhD from Harvard. Togo West is Chairman of Tli Leadership Group with a law degree from Howard University (all biographical information obtained from the BMS company website).

Merck is one of the biggest pharmaceutical companies in the world today. Although encountered with success, it still faces many problems today while trying to be the market leader competing against its competition. While being research and development driven company, Merck now has to go beyond R&D to stay competitive in the pharmaceutical industry. The main issue that seems to come up is that how far it can progress with the dual challenge of hitting peak annual financial performance while keeping the research pipeline full continued to weigh on senior management. Through the late 80s to early 90s, Merck was able to boast

The CEO and Co-founder of Seattle Genetics, Dr. Clay Siegall, recently sat down for an interview with Inspirey. Seattle Genetics is a biotech firm whose specialty is developing drugs to help combat fatal diseases like cancer where there has not been significant drug improvement for decades. Dr. Siegall who holds a Ph.D. in Genetics from George Washington University and a B.S. Degree in Zoology from the University of Maryland stated in his interview with Inspirey that he has always had an interested in medicine and the use of technology. This interest led him to fulfill a desire of becoming his own boss, by taking control of his own patents, products, and developments.

Brain Farley is the chief executive officer of Entellus Medical, a position he has held since 2010. Since 2008, Mr. Farley has served on the board of directors and in 2014 he was elected chairman of the board. Mr. Farley has extensive experience in the biotechnology industry, holding a B.S. in Biomedical Engineering and a Masters in Electrical Engineering, and he served in executive management positions with Eli Lilly, VNUS Medical Technologies and Guidant Corporation.

Question: To continue generating the returns enjoyed by the industry over the past decade, pharmaceutical companies would be forced to rethink how they identify and exploit opportunities to gain a competitive edge in an increasingly complex market ?

Change is when a person does not follow their everyday routine. They may want to try something different, or be forced to. Change can be for the good and the bad. Places can deal with change ranging from the weather, to the animals present, or the seasons changing. Also, objects can deal with change too. Objects like an iceberg can start to melt, or a forest fire can kill many trees in an area. As a human, we are the ones deciding on change. We are in a position to make big decisions and possibly even become a leader in order for change to happen. If one person starts to change, others will follow and hopefully, the change benefits all.

In 1998, University of Berkeley sought research funding through a deal with the company Novartis. The institution faced considerable controversy and backlash as many felt that such a deal violated what they deemed to be a university’s role and obligation to its community. Their belief that a partnership with such a large industry player would take away from the research that has benefited the citizens surrounding Berkeley and the state of California, overall. Faculty organizers of the deal argued that the deal would be advantageous due to the steep competition for state funding of research efforts. In addition, the deal would open up access to biological information held by Novartis, providing students and faculty with

Within each organization there should be effective leaders who should be able to maintain an organization’s vision and mission. These leaders are part of the management that can effectively lead a growing organization to succeed. There are various tools such as character traits, influence, persuasion, and change which can help an effective leader manage. A manger/leader should be prepared to persuade and influence others by using their character traits. Theories of leadership, management, and influence and change will be a major topic in this paper. This paper will discuss each of the elements of leadership and management, and how influence, persuasion, and change can affect the outcome.

In 2007, Genentech CEO Arthur Levinson, wanted to make his company a great place to work and recognized by the industry and magazines. This desire made Genentech adapt some culture that helped the employees to reduce stress and made the company one of the top

“The business is focused around the delivery of three strategic priorities which aim to increase growth, reduce risk, and improve our long-term financial performance. These priorities are: grow a diversified global business, deliver more products of value, and simplify the operating model.” (GSK 2015) The company works to diversify by creating a more balance business and product portfolio that will ensure sustainable sales growth. The company produces and distributes pharmaceuticals, vaccines, and consumer healthcare. The have redesigned research and development so it will be able to sustain an array of products that offer valuable improvements in treatment for patients and healthcare providers. They want to simplify the operating model by reducing complexity and becoming more efficient. They have a mission of being responsible in their delivery strategy to achieve success.